Behçet's disease: Current therapeutic perspectives

Current Treatment Options in Cardiovascular Medicine

Volumn 7, Issue 2, 2005, Pages 139-148

  Leiba, Merav ^a   Ehrenfeld, Michael ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ALPHA INTERFERON; ANESTHETIC AGENT; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BECLOMETASONE DIPROPIONATE; BETAMETHASONE; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; DEXAMETHASONE; ETANERCEPT; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MYDRIATIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORABASE; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; THALIDOMIDE; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACNE; ACUTE KIDNEY FAILURE; ALOPECIA; AMENORRHEA; ANOREXIA; APLASTIC ANEMIA; ARTHRALGIA; ARTHRITIS; ASPERGILLOSIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AVASCULAR NECROSIS; AZOOSPERMIA; BACKACHE; BEHCET DISEASE; BLOOD CLOTTING DISORDER; BLOOD DYSCRASIA; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BRAIN VASCULITIS; BRONCHITIS; BRONCHOSPASM; CARDIOMYOPATHY; CATARACT; CHILL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONVULSION; DEMYELINATING DISEASE; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DROWSINESS; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DYSMENORRHEA; DYSPEPSIA; ENDOCRINE DISEASE; ERYTHROCYTE APLASIA; EYE INFLAMMATION; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GENITAL ULCER; GINGIVA HYPERTROPHY; GLAUCOMA; GRANULOCYTOPENIA; HAIR LOSS; HALLUCINATION; HEADACHE; HEART INFARCTION; HEMOLYTIC ANEMIA; HEMORRHAGIC CYSTITIS; HIRSUTISM; HISTOPLASMOSIS; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOPLASIA; IMPAIRED GLUCOSE TOLERANCE; INDIGESTION; INDUCED ABORTION; INFECTION; INFERTILITY; INJECTION SITE REACTION; INSOMNIA; INTERSTITIAL PNEUMONIA; KIDNEY DISEASE; KIDNEY FAILURE; LEUKEMIA; LEUKOPENIA; LISTERIOSIS; LIVER ATROPHY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FIBROSIS; LIVER NECROSIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; LUNG TOXICITY; MALAISE; MEGALOBLASTIC ANEMIA; MEGALOCYTOSIS; MENTAL DISEASE; MOOD DISORDER; MOUTH ULCER; MYALGIA; MYCOSIS; MYOPATHY; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OLIGOSPERMIA; OPPORTUNISTIC INFECTION; ORTHOSTATIC HYPOTENSION; OSTEOPOROSIS; PANCREATITIS; PEPTIC ULCER; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHARYNGITIS; PHOTOSENSITIVITY; POLYNEUROPATHY; PSYCHOSIS; RETINOPATHY; REVIEW; SECOND CANCER; SEIZURE; SIDE EFFECT; SINUSITIS; SKIN ATROPHY; SKIN BRUISING; SKIN DEFECT; STOMATITIS; STRIA; STROKE; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOPHLEBITIS; THROMBOSIS; THYROID DISEASE; TUBERCULOSIS; ULCER; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; UVEITIS; VASCULAR DISEASE; VASCULAR SURGERY; VASCULITIS; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 27744471119     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-005-0015-1     Document Type: Review

References (41)

1. Adamantiades B: Sur un cas d'iritis a hypopyon recidivant. Ann d'Oculist 1931, 168:271-278.
2. Behçet H: Über rezidivierende aphthose durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937, 105:1152-1157.
3. Kaklamani VG, Vaiopoulos G, Kaklamanis PG: Behcet's disease. Semin Arthritis Rheum 1998, 27:197-217.
4. Davatchi F, Shahram F, Akbarian M, et al.: Behcet's disease: analysis of 3443 cases. APLAR J Rheumatol 1997, 1:2-5.
5. Zouboulis CC, Kötter I, Djawari D, et al.: Epidemiological features of Adamantiades-Behcet's disease in Germany and in Europe. Yonsei Med J 1997, 38:411-422.
6. Yurdakul S, Hamuryudan V, Yazici H: Behcet syndrome. Curr Opin Rheumatol 2004, 16:38-42.
7. Kone-Paut I, Gorchakoff-Molinas A, Weschler B, et al.: Paediatric Behcet's disease in France. Ann Rheum Dis 2002, 61:655-656.
8. Tursen U, Gurler A, Boyvat A: Evaluation of clinical findings according to sex in 2313 Turkish patients with Behcet's disease. Int J Dermatol 2003, 42:346-351.
9. Sano K, Yabuki K, Imagawa Y, et al.: The absence of disease-specific polymorphisms within the HLA-B51 gene that is the susceptible locus for Behcet's disease. Tissue Antigens 2001, 58:77-82.
10. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease [no authors listed]. Lancet 1990, 335:1078-1080.
11. Thompson AC, Nolan A, Lamey PJ: Minor aphthous oral ulceration: a double-blind cross-over study of beclomethasone dipropionate aerosol spray. Scott Med J 1989, 34:531-532.
12. Yurdakul S, Mat C, Tuzun Y, et al.: A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001, 44:2686-2692.
13. Kotter I, Durk H, Saal J, et al.: Therapy of Behcet's disease. Ger J Ophthalmol 1996, 5:92-97.
14. Kaklamani VG, Kaklamanis PC: Treatment of Behcet's disease-an update. Semin Arthritis Rheum 2001, 30:299-312.
15. Kontogiannis V, Powell RJ: Behcet's disease. Postgrad Med J 2000, 76:629-637.
16. Whitcup SM, Salvo Jr EC, Nussenblatt RB: Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol 1994, 118:39-45.
17. Barnes CG, Yazici H: Behcet's syndrome. Rheumatology 1999, 38:1171-1174.
18. Yazici H, Yurdakul S, Hamuryudan V: Behcet disease. Curr Opin Rheumatol 2001, 13:18-22.
19. Ozyazgan Y, Yurdakul S, Yazici H, et al.: Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Brit J Ophthalmol 1992, 76:241-243.
20. Sloper CML, Powel RJ, Dua HS: Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 1999, 106:723-728.
21. Fain O, Houng Du LT, Wechsler B, et al.: Pulse cyclophosphamide in Behcet's disease. In Behcet's Disease: Basic and Clinical Aspects. Edited by O'Duffy JD, Kokmen E. New York: Marcel Dekker Publishing; 1991:569-573.
22. Yazici H, Yurdakul S, Hamuryudan V: Behcet's syndrome: how should we treat it? Clin Immunother 1995, 3:102-107.
23. Shahram F, Davatchi F, Chams H. et al.: Comparing 3 methods of cytotoxic therapy in ophthalmologic lesions of Behcet's disease. In Behcet's Disease. Edited by Wechsler B, Godeau P. Amsterdam: Excerpta Medica; 1993:635-640.
24. Yazici H, Pazarli H, Barnes CG, et al.: A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 1990, 322:281-285.
25. Hamuryudan V, Ozyazgan Y, Hizli N, et al.: Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997, 40:769-774.
26. O'Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease. Am J Med 1984, 76:75-84.
27. O'Duffy JD: Behcet's syndrome. N Engl J Med 1990, 322:326-328.
28. Hirohata S, Suda H, Hashimoto T: Low-dose weekly methotrexate for progressive neuropsychiatric manifestations of Behcet's disease. J Neurol Sci 1998, 159:181-185.
29. Jorizzo JL, White WL, Wise CM, et al.: Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behcet's disease. J Am Acad Dermatol 1991, 24:973-978.
30. Nichols JC, Ince A, Akduman L, et al.: Interferon-alpha 2a treatment of neuro-Behcet disease. J Neuroophthalmol 2001, 21:109-111.
31. Zouboulis CC, Orfanos CE: Treatment of Adamantiades-Behcet disease with systemic interferon alfa. Arch Dermatol 1998, 134:1010-1016.
32. Alpsoy E, Durusoy C, Yilmaz E, et al.: Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 2002, 138:467-471.
33. Hamuryudan V, Mat C, Saip S. et al.: Thalidomide in the treatment of mucocutaneous lesions of the Behcet syndrome. A randomized double-blind, placebo-controlled trial. Ann Intern Med 1998, 128:443-450.
34. Ehrlich G: Behcet disease and the emergence of thalidomide. Ann Intern Med 1998, 128:494-495.
35. Yasui K, Ohta K, Kobayashi M, et al.: Successful treatment of Behcet disease with pentoxifylline. Ann Intern Med 1996, 124:891-893.
36. Leiba M, Seligsohn U, Sidi Y, et al.: Thrombophilic factors are not the leading cause of thrombosis in Behcet's disease. Ann Rheum Dis 2004, 63:1445-1449.
37. Nitecki SS, Ofer A, Karram T, et al.: Abdominal aortic aneurysm in Behcet's disease: new treatment options for an old challenging problem. Isr Med Assoc J 2004, 6:152-155.
38. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al.: Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001, 358:295-296.
39. Calamia KT: Current and future use of anti-TNF agents in the treatment of autoimmune, inflammatory disorders. Adamantiades-Behcet's Disease. In In Advances in Experimental Medicine and Biology, vol 528. Edited by Zouboulis CC. New York: Kluwer Academic/Plenum Publishers; 2003:545-549.
40. Ohno S, Nakamura S, Hori S: Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004, 31:1362-1368.
41. Melikoglu M, Ozyazgan Y, Fersko I, et al.: The response of treatment resistant uveitis in Behcet's syndrome to a TNF-alpha blocker, etanercept: an open study. Arthritis Rheum Abst 2002, 46:S181.